FOLR1 IHC
Use
The VENTANA FOLR1 (FOLR1‑2.1) RxDx Assay is an FDA‑approved qualitative immunohistochemical assay using a mouse monoclonal anti‑FOLR1 antibody, intended to assess Folate Receptor alpha (FRα) protein in formalin‑fixed, paraffin‑embedded (FFPE) ovarian cancer tissue. It serves as an aid in identifying patients with epithelial ovarian cancer (including primary peritoneal or fallopian tube cancer) who may be eligible for targeted therapy with the FRα‑directed drug ELAHERE™ (mirvetuximab soravtansine‑gynx); results should be interpreted by a qualified pathologist in context of histology and controls.
Special Instructions
Specimen requirements: FFPE tissue block preferred, or one unbaked, unstained H&E slide (required) plus two to three positively charged unstained slides (4–5 μm). Tissue must have ≥100 viable tumor cells. For storage/transport: use cold pack not in direct contact; NYS clients: provide date/time of collection. Level of service options: Global or Tech‑Only (stain only).
Limitations
Not provided.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
FFPE tissue block preferred or one unbaked unstained slide for H&E (required) plus 2‑3 positively charged unstained slides at 4‑5 μm
Storage Instructions
Use cold pack for transport; cold pack must not contact specimen